A Review of Recent Patents on the ASICs as a Key Drug Target

Author(s): Priscila L. Santos, Adriana G. Guimaraes, Rosana S.S. Barreto, Mairim R. Serafini, Jullyana S.S. Quintans, Lucindo J. Quintans-Junior.

Journal Name: Recent Patents on Biotechnology

Volume 9 , Issue 1 , 2015

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Acid-sensing ion channels (ASICs) are scattered various cells of human body. Drugs like amiloride has demonstrated nonspecific antagonism ASICs. Toxins, such as Psalmotoxin-1, have been used in animal models. There are no drugs available in the market whose action mechanism acts through these channels. We revised all patents relating to pharmaceutical formulations of applicability in ASICs. Drugs acting as antagonist in ASIC1 or ASIC3 channels seem to be the most promising targets. Patent data have suggested a variety of approaches for selective ASICs drugs, such as neuroprotective and analgesic. Studies analysis suggested that ASICs are promising targets for new drugs.

Keywords: ASIC, antagonist, drugs, review, patent, pain, inflammation.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 9
ISSUE: 1
Year: 2015
Page: [30 - 41]
Pages: 12
DOI: 10.2174/187220830901151111124125

Article Metrics

PDF: 65
HTML: 1
EPUB: 1
PRC: 1